Our Portfolio
Export table
FILTERS
Therapeutic Area
Select some options
Pharmaceutical Form
Select some options
Dossier Availability
Select some options
PRODUCT NAME
THERAPEUTIC AREA
PHARMACEUTICAL
FORM
STRENGTH
REFERENCE
PRODUCT
Antineoplastic & Immunomodulating Agents
Film-coated tablets
5 mg
10 mg
Xeljanz / Pfizer
Antineoplastic & Immunomodulating Agents
Prolonged-release tablet
11 mg
Xeljanz / Pfizer
Respiratory system
Inhalation powder
85/43 mcg
Ultibro Breezhaler / Novartis
Nervous system
Powder and solvent for prolonged-release suspension for injection
300 mg
400 mg
Abilify Maintena/Otsuka
Alimentary tract & metabolism
Film-coated tablets
5mg/500mg
5mg/850mg
5mg/1000 mg
12.5mg/500mg
12.5mg/850mg
12.5mg/1000mg
Synjardy / Boehringer Ingelheim
Alimentary tract & metabolism
Film-coated tablets
10 mg/5 mg
25 mg/5 mg
Glyxambi/ Boehringer Ingelheim
Antineoplastic & Immunomodulating Agents
Film-coated tablets
10 mg
20 mg
30 mg
Otezla / Celgene
Alimentary tract & metabolism
Film-coated tablets
2.5/500 mg
2.5/850 mg
2.5/1000 mg
Jentadueto / Boehringer Ingelheim
Cardiovascular System
Film-coated tablets
24mg / 26mg
49mg / 51mg
97mg / 103mg
Entresto / Novartis
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
^ This product is not offered for sale or made available in Germany due to patent (SPC) protection.
DISCLAIMER
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
Our Portfolio
Tofacitinib IR
THERAPEUTIC AREA
Antineoplastic & Immunomodulating Agents
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Xeljanz / Pfizer
STRENGTH
5 mg
| 10 mg
DOSSIER AVAILABILITY
Early stage
Tofacitinib SR^
THERAPEUTIC AREA
Antineoplastic & Immunomodulating Agents
PHARMACEUTICAL FORM
Prolonged-release tablet
REFERENCE PRODUCT
Xeljanz / Pfizer
STRENGTH
11 mg
DOSSIER AVAILABILITY
Early stage
Indacaterol / Glycopyrronium^
THERAPEUTIC AREA
Respiratory system
PHARMACEUTICAL FORM
Inhalation powder
REFERENCE PRODUCT
Ultibro Breezhaler / Novartis
STRENGTH
85/43 mcg
DOSSIER AVAILABILITY
2026 Q2
Glycopyrronium^
THERAPEUTIC AREA
Respiratory system
PHARMACEUTICAL FORM
Inhalation powder
REFERENCE PRODUCT
Seebri Breezhaler / Novartis
STRENGTH
44 mcg
DOSSIER AVAILABILITY
2025 Q4
Aripiprazole*
THERAPEUTIC AREA
Nervous system
PHARMACEUTICAL FORM
Powder and solvent for prolonged-release suspension for injection
REFERENCE PRODUCT
Abilify Maintena/Otsuka
STRENGTH
300 mg
| 400 mg
DOSSIER AVAILABILITY
2025 Q3
Empagliflozin* / Metformin^
THERAPEUTIC AREA
Alimentary tract & metabolism
PHARMACEUTICAL FORM
Film-coated tablets
REFERENCE PRODUCT
Synjardy / Boehringer Ingelheim
STRENGTH
5mg/500mg
| 5mg/850mg
| 5mg/1000 mg
| 12.5mg/500mg
| 12.5mg/850mg
| 12.5mg/1000mg
DOSSIER AVAILABILITY
2025 Q2
* Polpharma Group API
(1) BEQ study against Canadian reference product available
(2) BEQ study against Canadian reference product on-going
(3) BEQ study against Canadian reference product planned
^ This product is not offered for sale or made available in Germany due to patent (SPC) protection.
